全文获取类型
收费全文 | 64432篇 |
免费 | 4903篇 |
国内免费 | 214篇 |
专业分类
耳鼻咽喉 | 797篇 |
儿科学 | 1526篇 |
妇产科学 | 876篇 |
基础医学 | 8237篇 |
口腔科学 | 956篇 |
临床医学 | 6872篇 |
内科学 | 14072篇 |
皮肤病学 | 797篇 |
神经病学 | 6448篇 |
特种医学 | 2192篇 |
外国民族医学 | 5篇 |
外科学 | 11544篇 |
综合类 | 667篇 |
一般理论 | 52篇 |
预防医学 | 4375篇 |
眼科学 | 1232篇 |
药学 | 4530篇 |
中国医学 | 74篇 |
肿瘤学 | 4297篇 |
出版年
2023年 | 458篇 |
2022年 | 369篇 |
2021年 | 1851篇 |
2020年 | 1227篇 |
2019年 | 1812篇 |
2018年 | 2209篇 |
2017年 | 1546篇 |
2016年 | 1654篇 |
2015年 | 1893篇 |
2014年 | 2738篇 |
2013年 | 3406篇 |
2012年 | 5305篇 |
2011年 | 5522篇 |
2010年 | 2970篇 |
2009年 | 2723篇 |
2008年 | 4464篇 |
2007年 | 4557篇 |
2006年 | 4340篇 |
2005年 | 4133篇 |
2004年 | 3689篇 |
2003年 | 3521篇 |
2002年 | 3158篇 |
2001年 | 476篇 |
2000年 | 364篇 |
1999年 | 405篇 |
1998年 | 560篇 |
1997年 | 412篇 |
1996年 | 327篇 |
1995年 | 345篇 |
1994年 | 293篇 |
1993年 | 276篇 |
1992年 | 244篇 |
1991年 | 196篇 |
1990年 | 159篇 |
1989年 | 140篇 |
1988年 | 143篇 |
1987年 | 128篇 |
1986年 | 111篇 |
1985年 | 110篇 |
1984年 | 145篇 |
1983年 | 112篇 |
1982年 | 122篇 |
1981年 | 108篇 |
1980年 | 122篇 |
1979年 | 83篇 |
1978年 | 79篇 |
1977年 | 73篇 |
1976年 | 51篇 |
1975年 | 46篇 |
1974年 | 57篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Christopher Meyers 《The Hastings Center report》2023,53(1):26-27
In Abram Brummett and Erica K. Salter's excellent paper, “Mapping the Moral Terrain of Clinical Deception,” they rightly note that it is sometimes ethically appropriate for health care professionals to deceive patients and families. However, they also note that because doing so violates a prima facie duty of honesty, the ethical burden of proof falls upon the deceiver. Hence, they also provide a sophisticated framework for determining whether any given case is warranted. I applaud their overall approach but also critique some of their claims, in particular, their conclusion that lies of commission require greater justification than those of omission and their conflation of the principles of beneficence and nonmaleficence. I also urge them to give greater attention to how power asymmetries should be accounted for and to the impact such deceptive choices might have on the clinician's character. 相似文献
2.
3.
4.
5.
Junyu Wang Daniel S. Weller Christopher M. Kramer Michael Salerno 《NMR in biomedicine》2022,35(5):e4661
The objective of the current study was to develop and evaluate a DEep learning-based rapid Spiral Image REconstruction (DESIRE) technique for high-resolution spiral first-pass myocardial perfusion imaging with whole-heart coverage, to provide fast and accurate image reconstruction for both single-slice (SS) and simultaneous multislice (SMS) acquisitions. Three-dimensional U-Net–based image enhancement architectures were evaluated for high-resolution spiral perfusion imaging at 3 T. The SS and SMS MB = 2 networks were trained on SS perfusion images from 156 slices from 20 subjects. Structural similarity index (SSIM), peak signal-to-noise ratio (PSNR), and normalized root mean square error (NRMSE) were assessed, and prospective images were blindly graded by two experienced cardiologists (5: excellent; 1: poor). Excellent performance was demonstrated for the proposed technique. For SS, SSIM, PSNR, and NRMSE were 0.977 [0.972, 0.982], 42.113 [40.174, 43.493] dB, and 0.102 [0.080, 0.125], respectively, for the best network. For SMS MB = 2 retrospective data, SSIM, PSNR, and NRMSE were 0.961 [0.950, 0.969], 40.834 [39.619, 42.004] dB, and 0.107 [0.086, 0.133], respectively, for the best network. The image quality scores were 4.5 [4.1, 4.8], 4.5 [4.3, 4.6], 3.5 [3.3, 4], and 3.5 [3.3, 3.8] for SS DESIRE, SS L1-SPIRiT, MB = 2 DESIRE, and MB = 2 SMS-slice-L1-SPIRiT, respectively, showing no statistically significant difference (p = 1 and p = 1 for SS and SMS, respectively) between L1-SPIRiT and the proposed DESIRE technique. The network inference time was ~100 ms per dynamic perfusion series with DESIRE, while the reconstruction time of L1-SPIRiT with GPU acceleration was ~ 30 min. It was concluded that DESIRE enabled fast and high-quality image reconstruction for both SS and SMS MB = 2 whole-heart high-resolution spiral perfusion imaging. 相似文献
6.
Patrick Demkowicz BS Renelle Pointdujour-Lim MD Sofia Miguez BA Yesung Lee BS Bailey S. C. L. Jones BS Christopher A. Barker MD Marcus Bosenberg MD PhD David H. Abramson MD Alexander N. Shoushtari MD Harriet Kluger MD Jasmine H. Francis MD Mario Sznol MD Mathieu F. Bakhoum MD PhD 《Cancer》2023,129(20):3275-3286
7.
8.
Deshmukh Abhishek J. DeSimone Christopher V. 《Journal of interventional cardiac electrophysiology》2022,65(1):263-265
Journal of Interventional Cardiac Electrophysiology - 相似文献
9.
Ha Audrey Y. Do Bao H. Bartret Adam L. Fang Charles X. Hsiao Albert Lutz Amelie M. Banerjee Imon Riley Geoffrey M. Rubin Daniel L. Stevens Kathryn J. Wang Erin Wang Shannon Beaulieu Christopher F. Hurt Brian 《Journal of digital imaging》2022,35(3):524-533
Journal of Digital Imaging - Scoliosis is a condition of abnormal lateral spinal curvature affecting an estimated 2 to 3% of the US population, or seven million people. The Cobb angle is the... 相似文献
10.
Naveen Pemmaraju MD Jacqueline S. Garcia MD Andrew Perkins MBBS PhD Jason G. Harb PhD Andrew J. Souers PhD Michael E. Werner PhD Christopher M. Brown PhD Francesco Passamonti MD 《Cancer》2023,129(22):3535-3545
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment. 相似文献